Q-omics provides the consensus-scored POT1 profile across patient tissues and cancer cell-line models. POT1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, POT1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, POT1 RNA expression shows 20,322 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where POT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POT1 survival associations across molecular data types. POT1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POT1 RNA expression–survival associations across cancer types. High POT1 expression shows unfavorable associations in PAAD, KICH and MESO, but favorable associations in KIRC, SKCM and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for POT1 RNA expression.
This table summarizes POT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POT1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, KIRC, COAD and BLCA. The HNSC box plot shows higher POT1 RNA expression in tumor versus normal tissue (log2 FC = +1.375, t-test p < 0.001).
This table shows molecular features associated with POT1 in patient tissues and cancer cell lines. In patient samples, POT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, POT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
